Abstract

The specific research interests are: 1) To participate fully in the clinical studies of the CCG by enrolling as many eligible children with primary or recurrent malignant disorders on CCG studies as possible, including Phase I, II and III studies; 2) To continue to provide scientific and administrative expertise to CCG through active participation in Strategy groups, Scientific and Discipline Committees and study committees; 3) To enhance fundamental understanding of biology and treatment of childhood cancer, focusing particularly on the areas of bone marrow transplantation, AML, bone and soft tissue sarcomas, brain tumors, and new agent development; 4) To conduct pilot biologic and therapeutic studies in hematopoietic stem cell transplantation and peripheral blood stem cell support of intensive chemotherapy to provide preliminary data for consideration of these approaches by the CCG.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA010382-35
Application #
6328855
Study Section
Subcommittee G - Education (NCI)
Program Officer
Smith, Malcolm M
Project Start
1976-12-01
Project End
2002-11-30
Budget Start
2000-12-01
Budget End
2001-11-30
Support Year
35
Fiscal Year
2001
Total Cost
$223,693
Indirect Cost

  Institution

Name
Seattle Children's Hospital
Department
Type
DUNS #
048682157
City
Seattle
State
WA
Country
United States
Zip Code
98105

  Publications

Geyer, J Russell; Sposto, Richard; Jennings, Mark et al. (2005) Multiagent chemotherapy and deferred radiotherapy in infants with malignant brain tumors: a report from the Children's Cancer Group. J Clin Oncol 23:7621-31
Neudorf, Steven; Sanders, Jean; Kobrinsky, Nathan et al. (2004) Allogeneic bone marrow transplantation for children with acute myelocytic leukemia in first remission demonstrates a role for graft versus leukemia in the maintenance of disease-free survival. Blood 103:3655-61
Dudkin, Vadim Y; Miller, Justin S; Danishefsky, Samuel J (2004) Chemical synthesis of normal and transformed PSA glycopeptides. J Am Chem Soc 126:736-8
Sievers, Eric L; Lange, Beverly J; Alonzo, Todd A et al. (2003) Immunophenotypic evidence of leukemia after induction therapy predicts relapse: results from a prospective Children's Cancer Group study of 252 patients with acute myeloid leukemia. Blood 101:3398-406
Davies, Stella M; Bhatia, Smita; Ross, Julie A et al. (2002) Glutathione S-transferase genotypes, genetic susceptibility, and outcome of therapy in childhood acute lymphoblastic leukemia. Blood 100:67-71
Wells, Robert J; Reid, Joel M; Ames, Matthew M et al. (2002) Phase I trial of cisplatin and topotecan in children with recurrent solid tumors: Children's Cancer Group Study 0942. J Pediatr Hematol Oncol 24:89-93
Lange, Beverly J; Bostrom, Bruce C; Cherlow, Joel M et al. (2002) Double-delayed intensification improves event-free survival for children with intermediate-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood 99:825-33
Ou, Shu Xiao; Han, Dehui; Severson, Richard K et al. (2002) Birth characteristics, maternal reproductive history, hormone use during pregnancy, and risk of childhood acute lymphocytic leukemia by immunophenotype (United States). Cancer Causes Control 13:15-25
Cairo, M S; Krailo, M D; Morse, M et al. (2002) Long-term follow-up of short intensive multiagent chemotherapy without high-dose methotrexate ('Orange') in children with advanced non-lymphoblastic non-Hodgkin's lymphoma: a children's cancer group report. Leukemia 16:594-600
Wells, R J; Arthur, D C; Srivastava, A et al. (2002) Prognostic variables in newly diagnosed children and adolescents with acute myeloid leukemia: Children's Cancer Group Study 213. Leukemia 16:601-7

Showing the most recent 10 out of 25 publications